Change in formulation and its potential clinical and pharmacoeconomic value: Example of extended release venlafaxine

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1089-1094

  Haeusler, Jean Marc C ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Adherence; Cost; Formulation; Pill burden; Venlafaxine

Indexed keywords

VENLAFAXINE;

AGITATION; DIZZINESS; DRUG APPROVAL; DRUG CAPSULE; DRUG COST; DRUG FORMULATION; DYSPHORIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; MAJOR DEPRESSION; NAUSEA; NOTE; PANIC; PATIENT COMPLIANCE; SIDE EFFECT; SOCIAL PHOBIA; TABLET; TREMOR; WITHDRAWAL SYNDROME;

CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 67649394250     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902858303     Document Type: Note

References (41)

1. US Food and Drug Administration. Guidance for Industry: Applications Covered by Section 505(b)(2). http://www.fda.-gov/cder/guidance/2853dft.pdf. Accessed December 12, 2008
2. US Prescribing Information Venlafaxine Extended Release Tablets (venlafaxine hydrochloride). Osmotica Pharmaceutical Corp., Wilmington, NC, May, 2008
3. US Food and Drug Administration. Drugs@FDA [Query for Effexor]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed December 12, 2008
4. US Prescribing Information Effexor XR® (venlafaxine hydrochloride) Extended-Release Capsules. Wyeth Pharmaceuticals Inc., Philadelphia, PA, 2008
5. Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006;6:30 (Pubitemid 44270133)
6. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404 (Pubitemid 34499333)
7. Thase ME. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241 (Pubitemid 32183606)
8. Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001;15:643-669 (Pubitemid 32848345)
9. Drugs.com. Top 200 Drugs for 2007 by Sales. http://www.drugs.com/top200. html. Accessed December 12, 2008
10. Sobocki P, Ekman M, Ovanfors A, et al. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int J Clin Pract 2008;62:623-632 Epub 2008 Feb 15 (Pubitemid 351348039)
11. US Food and Drug Administration. Electronic Orange Book [Query for venlafaxine]. http://www.fda.gov/cder/ob/docs/queryai.htm. Accessed December 12, 2008
12. US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations - 28th Edition. http://www.fda.gov/cder/orange/obannual. pdf. Accessed December 12, 2008
13. Vivian JC. Generic-substitution laws. US Pharm 2008;33:30-34
14. PriceRx. Wholesale acquisition cost for Effexor XR and venlafaxine extended release tablets. Medispan, February 17, 2009
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497 (Pubitemid 41127293)
16. Atreja A, Bellam N, Levy SR. Strategies to enhance patient adherence: making it simple. Med Gen Med 2005;7:4 (Pubitemid 41349762)
17. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-2304 (Pubitemid 37076320)
18. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-1152 (Pubitemid 40720739)
19. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007;15:257-263 (Pubitemid 47282034)
20. Puigventós F, Riera M, Delibes C et al. [Adherence to antiretroviral drug therapy. A systematic review]. Med Clin (Barc) 2002;119:130-137
21. Halkitis P, Palamar J, Mukherjee P. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. AIDS Patient Care STDS 2008;22:323-335 (Pubitemid 351562967)
22. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials 2002;3:371-378 (Pubitemid 35189880)
23. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001;33:865-872 (Pubitemid 32831844)
24. Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr Scand 2000;101:50-56 (Pubitemid 30691136)
25. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74
26. Hylan TR, Dunn RL, Tepner RG, et al. Gaps in antidepressant prescribing in primary care in the United Kingdom. Int Clin Psychopharmacol 1998;13:235-243 (Pubitemid 28550056)
27. Demyttenaere K, Adelin A, Patrick M, et al. Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008;23:36-42 (Pubitemid 350294868)
28. Burton WN, Chen CY, Conti DJ, et al. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care 2007;13:105-112 (Pubitemid 46303172)
29. Stein MB, Cantrell CR, Sokol MC, et al. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006;57:673-680
30. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008;299:1922-1928 (Pubitemid 351574922)
31. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 2007;22:864-871 (Pubitemid 46763978)
32. Bambauer KZ, Safran DG, Ross-Degnan D, et al. Depression and cost-related medication nonadherence in Medicare beneficiaries. Arch Gen Psychiatry 2007;64:602-608 (Pubitemid 46718293)
33. Bosworth HB, Voils CI, Potter GG, et al. The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiatry 2008;23:129-134 (Pubitemid 351308491)
34. Akerblad AC, Bengtsson F, von Knorring L, Ekselius L. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 2006;21:117-124 (Pubitemid 43740320)
35. Herrmann S, McKinnon E, John M, et al. Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care. Intern Med J 2008;38:8-15
36. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol 2008;33:867-874
37. Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm 2007;13:2-12
38. Bender B, Zhang L. Negative affect, medication adherence, and asthma control in children. J Allergy Clin Immunol 2008;122:490-495
39. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-2312 (Pubitemid 350033432)
40. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 2008;27:103-112 (Pubitemid 351198595)
41. Ye X, Gross CR, Schommer J, et al. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007;29:2748-2757